bioMérieux S.A. (EPA:BIM)

Market Cap	13.28B
Revenue (ttm)	3.81B
Net Income (ttm)	411.30M
Shares Out	118.01M
EPS (ttm)	3.47
PE Ratio	32.43
Forward PE	25.04
Dividend	0.85 (0.74%)
Ex-Dividend Date	Jun 7, 2024

Volume	216,019
Average Volume	102,802
Open	114.20
Previous Close	114.60
Day's Range	112.40 - 114.80
52-Week Range	88.25 - 117.60
Beta	0.27
RSI	48.19
Earnings Date	Mar 14, 2025

About bioMérieux

bioMérieux S.A. develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemaseproducing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO BACT/ALERT 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction (PCR) system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; V...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1963
• Employees: 13,982
• Stock Exchange: Euronext Paris
• Ticker Symbol: BIM

Financial Performance

In 2023, bioMérieux's revenue was 3.67 billion, an increase of 2.38% compared to the previous year's 3.59 billion. Earnings were 357.60 million, a decrease of -20.95%.